# Efficacy and Safety of Rifaximin-α in Treating MASLD

> **NCT07381257** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Metabolic Dysfunction-Associated Steatotic Liver Disease

## Interventions

- **DRUG:** Rifaximin-α (Alfa Wassermann S.p.A., Italy)

## Key facts

- **NCT ID:** NCT07381257
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07381257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07381257, "Efficacy and Safety of Rifaximin-α in Treating MASLD". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07381257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*